HOMEwww.epgonline.orgDRUGSwww.epgonline.orgDISEASE KNOWLEDGEwww.epgonline.orgGUIDELINESwww.epgonline.orgCLINICAL TRIALSwww.epgonline.orgREGISTERwww.epgonline.orgSEARCH
Members
Why a doctor should
Username/Email

Password ()




EPG on Twitter EPG Online Twitter
EPG Online Blog EPG Online Blog
EPG Online Disease Knowledge Centres Feed Disease Knowledge
Recent UK Drug Updates Drug Updates
EPG Search
Search
Languages

Xatral XL 10mg (BPH) overview

Benign prostatic hypertrophy. (BPH)

banner_pass = 1

Please register to access disease diagnosis, patient management, physician tools.
By viewing the content of this web page you are both confirming your status as a healthcare professional and agreeing to our terms of use.

Change language Current language database: English
 
 
Related DrugsDrug Details
Xatral XL 10mg (BPH)
Drug Class Description :

Uroselective a1 -blocker (alpha- blockers / alpha-adrenoceptor blocking drugs).

Generic Name :

Alfuzosin

Drug description :

Prolonged release tablets.

Presentation :

Tablets, alfuzosin hydrochloride 10mg .

Indications :

Benign prostatic hypertrophy. (BPH)

Adult Dosage :

Xatral XL should be swallowed whole.

BPH: The recommended dose is one 10mg tablet to be taken once daily after a meal.

AUR: In patients 65 years and older, one 10 mg tablet daily after a meal to be taken from the first day of catheterisation. The treatment should be administered for 3-4 days, 2-3 days during catheterisation and 1 day after its removal. In this indication no benefit has been established in patients under 65 years of age or if treatment is extended beyond 4 days.

 

Paediatric Population

Efficacy of Xatral XL has not been demonstrated in children aged 2 to 16 years. Therefore Xatral XL is not indicated for use in the paediatric population.

Child Dosage :

Efficacy of Xatral XL has not been demonstrated in children aged 2 to 16 years. Therefore Xatral XL is not indicated for use in the paediatric population.

Elderly Dosage :

In patients 65 years and older, one 10 mg tablet daily after a meal to be taken from the first day of catheterisation. The treatment should be administered for 3-4 days, 2-3 days during catheterisation and 1 day after its removal. In this indication no benefit has been established in patients under 65 years of age or if treatment is extended beyond 4 days.

Contra Indications :

Hypersensitivity to alfuzosin. History of orthostatic hypotension. Co-administration with other alpha-blockers. Severe hepatic insufficiency.

Special Precautions :

Renal or hepatic impairment. Hypertension; monitor BP regularly, particularly at start of treatment. Coronary insufficiency; discontinue if angina deteriorates. Withdraw 24 hours before anaesthesia.

Interactions :

Other a-blockers, antihypertensives. antihypertensives.

Adverse Reactions :

Faintness, vertigo, dizziness or malaise, headache, GI upset. Also, orthostatic hypotension, syncope, tachycardia, palpitations, chest pain, fatigue, drowsiness, rash, pruritus, flushes, oedema.

Manufacturer :

Sanofi-Synthelabo

Drug Availability :

(POM)

Drug Updated :

23 November 2011

Related Drugs - Renal & bladder disorders
Alzheimer's disease (AD) is a progressive, neurodegenerative disease which will affect most of us at one point in time, and it’s prevalence increases with age. Ophthalmics - understanding, management, diagnosis and treatment information Cystic Fibrosis Cholesterol - This knowledge centre contains a comprehensive coverage of cholesterol related information, cardivascular disease management guidelines and treatment options.
New and updated Drugs
UK Drugs EPG Medical News Feed
Spanish Drugs EPG Medical News Feed
German Drugs EPG Medical News Feed
Norweigan Drugs EPG Medical News Feed
Netherlands Drugs EPG Medical News Feed
Swedish Drugs EPG Medical News Feed
French Drugs EPG French Drugs Feed
Portuguese Drugs EPG Portuguese Drugs Feed
Italian Drugs EPG Italian Drugs Feed

Atopic Dermatitis

Atopic Dermatitis

CONNECT

DISEASE CENTRES Disease Centres feed

AFFILIATE PARTNERS

QUICK SEARCH

GUIDELINES UK Drug Data Feed

DRUG DATA UK Drug Data Feed

REFERENCES